An expected delay in a key step in CK Hutchison's planned sale of its Panama ports to a U.S. group, a deal blasted by Chinese ...

Several studies have been done on the myriad list of side effects that come from popular weight loss drugs.  A new study ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

Scientists are trying to tackle Alzheimer's from all angles, and a new study adds to the growing evidence that semaglutide, a ...

CHICAGO -- Coming this weekend, the American College of Cardiology (ACC) annual conference will feature research exploring ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

A new clinical trial ... were divided into a placebo group (no medication) and a drug group to see if those taking oral semaglutide were more or less likely to experience major cardiac events.

Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...

A popular weight-loss drug used by celebrities overseas has been approved by New Zealand’s medicine regulatory body, with its ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

Semaglutide, the active ingredient in Ozempic, may help fight Alzheimer’s. Researchers found it reduces brain inflammation and improves memory in mice with Alzheimer’s-like symptoms.